Subscribe
Core coverageSMMT

Company profile / SMMT

Summit Therapeutics

Clinaptis stanceNeutral
ConvictionMedium
Ticker
SMMT
Exchange
NASDAQ
Coverage
Standard profile
Updated
Oct 15, 2026
Oncology / Immuno-oncology

Clinical-stage oncology company developing ivonescimab, a PD-1/VEGF bispecific antibody licensed from Akeso, across a broad global program led by non-small cell lung cancer.

01 / Clinaptis view

The current read

Neutral, with increasing confidence in the asset but less certainty around the value already reflected in the security.

  1. Ivonescimab has assembled an unusually strong body of evidence for a single-asset oncology company. Global HARMONi demonstrated a statistically significant progression-free-survival benefit in post-TKI EGFR-mutated NSCLC, while longer follow-up has shown a consistent favorable overall-survival trend across Western and Asian patients. Positive head-to-head survival results from the China-based HARMONi-2 and HARMONi-6 studies further support the biological rationale for combining PD-1 and VEGF inhibition in one molecule.
  2. AstraZeneca's $2 billion strategic investment substantially reduces financing risk and strengthens external validation of ivonescimab as a potential combination backbone. The remaining question is not whether the molecule is active, but how broadly that activity translates into global regulatory approvals and commercially differentiated first-line indications. We therefore remain Neutral: the clinical trajectory is constructive, but the valuation already assigns meaningful credit to a broad oncology franchise that has not yet been established outside China.
02 / Consensus gap

Where the market may differ

The market may treat ivonescimab's China results, expanding partnership network and AstraZeneca investment as sufficient evidence that it can become a broadly used successor to conventional PD-1 therapy. We think that conclusion remains premature.

  1. The November FDA decision can validate the global HARMONi package, but the initial post-TKI EGFR-mutated NSCLC indication is relatively narrow and does not by itself prove that ivonescimab can displace established immunotherapy combinations in larger first-line markets. The more consequential evidence will come from global head-to-head studies such as HARMONi-3, where efficacy, safety and geographic consistency must support a meaningful advantage over entrenched standards of care.
Coverage state
Standard profile
What the review turns on
Key variable

Whether global trials establish ivonescimab as a differentiated first-line treatment backbone rather than an approvable therapy confined to narrower settings.

Next catalyst

Ivonescimab · FDA PDUFA for post-TKI EGFR-mutated NSCLC · Nov 14, 2026

03 / Pipeline

Key programs

5 assets · 5 programs

AssetIndicationStageNext event
Ivonescimab
Post-TKI EGFR-mutated NSCLC
Under FDA review
FDA PDUFA decision on Nov 14, 2026
Ivonescimab + chemotherapy
First-line NSCLC
Phase 3
HARMONi-3 squamous-cohort final PFS analysis expected in H2 2026
Ivonescimab + mFOLFOX6
First-line metastatic colorectal cancer
Phase 3
HARMONi-GI3 enrollment and clinical progression
Ivonescimab + enfortumab vedotin
First-line urothelial carcinoma
Phase 2/3
HARMONi-GU1 global site activation and enrollment
Ivonescimab + Datroway
First-line triple-negative breast cancer
Phase 3
Planned Phase 3 study initiation
04 / Connected research

Published on SMMT

View full archive
  1. 01

    Summit's (SMMT) Ivonescimab Has a Narrow Path to a PFS Win in Squamous NSCLC

    After a likely interim miss, can ivonescimab still beat pembrolizumab plus chemotherapy at HARMONi-3's final PFS bar of HR ~0.79 in squamous NSCLC, and how far has the miss cut its ~84% pre-interim odds?

    Read